Navigation Links
ACell's CEO to Present at Rodman & Renshaw's 2009 Annual Global Investment Conference
Date:9/2/2009

COLUMBIA, Md., Sept. 2 /PRNewswire/ -- ACell, Inc. is announcing its participation at Rodman & Renshaw's 2009 Annual Global Investment Conference.

The conference will be held September 9, 2009 through September 11, 2009 at the New York Palace Hotel in New York City. James DeFrancesco, Chief Executive Officer and President, is scheduled to make an investor presentation on September 11th beginning at 9:10 AM (EDT) in the Hubbard Room. The presentation is expected to take approximately 25 minutes. Investors and strategic partners interested in ACell's proprietary technology are encouraged to contact the company for private one on one discussion while attending the conference.

Mr. DeFrancesco's presentation will provide an update on ACell's regenerative medicine technology and share clinical results of recently completed cases. ACell introduced its wound care devices utilizing a major marketing partner last January. Now, with the recent release of several new extracellular matrix (ECM) surgical devices, ACell is targeting the US plastic surgery, hernia and trauma markets. Several orthopedic products are scheduled for release next year. The company has recently received significant media coverage for the involvement of its MatriStem((R)) MicroMatrix(TM) in re-growing severed fingertips.

ACell Inc.

ACell is a private company with multiple US and international patents for its proprietary UBM (Urinary Bladder Matrix) ECM technology. ACell's advanced bio-scaffold devices consist of an intact epithelial basement membrane, naturally derived bioactive molecules and multiple collagen types known to assist the body in the regeneration of new tissues. Commercially branded as MatriStem((R)), UBM can be used in a broad range of regenerative medicine applications. ACell currently has five FDA 510(k) clearances addressing wound care and various surgical indications.

www.acell.com


'/>"/>
SOURCE ACell, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Transcept Pharmaceuticals to Present at the BioCentury Thomson Reuters Newsmakers in the Biotech Industry Conference on September 16, 2009
2. BioMarin to Present at the Baird Healthcare Conference
3. Poniard Pharmaceuticals To Present at Three Upcoming Investor Conferences in September
4. NeurogesX to Present at Upcoming Fall Conferences
5. Repligen to Present at the Rodman & Renshaw 11th Annual Healthcare Conference Wednesday, September 9th, 2:25 p.m. EDT
6. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
7. Jiangbo Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
8. Express Scripts to Present at Investor Conferences
9. ERT to Present at Bairds 2009 Health Care Conference on September 9, 2009
10. PharmAthene to Present at the Rodman and Renshaw Annual Global Investment Conference September 10, 2009
11. PAREXEL International to Present at Robert Baird 2009 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , ... June 23, 2016 , ... ... pleased to announce the launch of their brand, UP4™ Probiotics, into Target stores ... 35 years, is proud to add Target to its list of well-respected retailers. ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology:
(Date:3/31/2016)... March 31, 2016   ... or the "Company") LegacyXChange is excited to ... its soon to be launched online site for trading ... ) will also provide potential shareholders a sense ... technology to an industry that is notorious for fraud. ...
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
(Date:3/21/2016)... , March 22, 2016 ... with passcodes for superior security   ... leading provider of secure digital communications services, today announced ... technology and offer enterprise customers, particularly those in the ... recognition and voice authentication within a mobile app, alongside, ...
Breaking Biology News(10 mins):